Biosimilar Newsletter Archive

41. 11.21.24 -- Safety Cabinets' Essential Role In EU GMP Annex 1 11/21/2024
    11/21/24 Biosimilar Development Newsletter
42. 11.14.24 -- Take The Next Step Towards Scaling-Up 11/14/2024

    11/14/24 Biosimilar Development Newsletter

43. 11.14.24 -- What's Next After FDA's DSCSA Extension? 11/14/2024
    11/14/24 Biosimilar Development Newsletter
44. 11.07.24 -- Reduce Time To Market With Efficient Vial Selection 11/7/2024

    11/07/24 Biosimilar Development Newsletter

45. 11.07.24 -- Data Quality Issues At The Heart Of FDA's DSCSA Troubles 11/7/2024
    11/07/24 Biosimilar Development Newsletter
46. 10.31.24 -- Key Considerations For Aseptic Filling 10/31/2024

    10/31/24 Biosimilar Development Newsletter

47. 10.31.24 -- Is The Downstream Biomanufacturing Bottleneck Over? 10/31/2024
    10/31/24 Biosimilar Development Newsletter
48. 10.24.24 -- Why Aren't QC Labs Fully Automated Yet? 10/24/2024
    10/24/24 Biosimilar Development Newsletter
49. 10.18.24 -- Resources For Trouble-Free Validation 10/18/2024

    10/18/24 Biosimilar Development Newsletter

50. 10.17.24 -- Outsourcing Considerations For Complex Protein Development 10/17/2024
    10/17/24 Biosimilar Development Newsletter